NMTC (NeuroOne Medical Technologies) Moat Score: 5/10 (As of Jul. 02, 2026)


NMTC NeuroOne Medical Technologies Corp NMTC
39 GF Score
Price $3.01
GF Value $6.60
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is NeuroOne Medical Technologies Moat Score?

NeuroOne Medical Technologies NMTC -0.66% 39 Moat Score is 5 as of Jul. 02, 2026. GuruFocus rates NMTC with a GF Score™ of 39/100 and a GF Value™ of $6.60 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 846 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks better than 91.25% on this metric.

NeuroOne Medical Technologies has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

NeuroOne Medical Technologies has Narrow Moat: NMTC has a solid narrow moat with its innovative medical technologies and patents. The company's focus on neurological applications provides some customer loyalty and switching costs, but the competitive medical device market limits its moat strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes NeuroOne Medical Technologies might have Narrow Moat - Solid narrow moat.

NeuroOne Medical Technologies  (NAS:NMTC) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

NeuroOne Medical Technologies Moat Score Related Terms

NMTC vs RDGL, TANAF, MODD: Moat Score Comparison

For the Medical Devices subindustry, NeuroOne Medical Technologies's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Moat Score distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's Moat Score falls into.


NMTC
39GF Score
NeuroOne Medical Technologies Corp NMTC
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
NeuroOne Medical Technologies (NMTC) has a Moat Score of 5 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, NeuroOne Medical Technologies ranks #74 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is NeuroOne Medical Technologies' Moat Score too high?
NeuroOne Medical Technologies' current Moat Score is 5. Based on the distribution chart, NeuroOne Medical Technologies ranks #74 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Moat Score compare to RDGL and TANAF?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #74 out of 846 companies for Moat Score. This places NeuroOne Medical Technologies in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. NeuroOne Medical Technologies's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.60, compared to a current price of $3.01 — trading 54.4% below its estimated fair value. The current Moat Score is 5. NeuroOne Medical Technologies' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Moat Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued. The current stock price of $3.01 is trading 54.4% below its estimated GF Value™ of $6.60. GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.

Key valuation signals for NMTC:

  • Moat Score: 5
  • GF Value™: $6.60 vs. price of $3.01 (54.4% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroOne Medical Technologies Business Description

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
39GF Score

Get the complete analysis for NMTC

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.01
Price
$6.60
GF Value